How researchers distinguish therapeutic, ceremonial and recreational use

The way societies talk about psilocybin use rarely begins with the molecule itself. Instead, it begins with a question of framing: why, where, with whom, and toward what end a substance is used. In the research literature and in drug policy, three broad categories — therapeutic, ceremonial, and recreational — are used to describe different contexts of use. These distinctions are not merely descriptive. They shape how clinical trials are designed, how regulators schedule substances, how courts interpret religious freedom, and how public health systems weigh benefit against risk.

The categories overlap in practice, and researchers are increasingly candid about their limitations. A person using psilocybin in a clinical trial may have a spiritually significant experience; a person in a ceremony may experience psychological relief; a person using outside any formal setting may gain insight they later describe as therapeutic. Despite this blur, the frames remain analytically useful — and legally consequential.

Therapeutic use: the clinical frame

In the therapeutic frame, psilocybin is administered under medical supervision, typically within a structured protocol that includes screening, preparation, one or more dosing sessions, and follow-up integration. The model used in modern clinical trials — refined at institutions such as Johns Hopkins and Imperial College London — involves a therapist or guide present throughout, a controlled environment designed to minimise external stimulation, and psychological support before and after the session.

This frame is defined by intentionality, oversight, and standardisation. Researchers distinguish it from other forms of use primarily by its clinical safeguards: trained facilitators, medical screening for contraindications, and structured integration. In the regulatory world, the therapeutic frame is the one that has opened doors. It is the basis for the FDA's breakthrough therapy designation for psilocybin-assisted therapy and for the TGA's 2023 rescheduling of psilocybin for treatment-resistant depression in Australia. Both pathways are narrow, restricted to specific clinical indications and delivered under professional supervision.

Ceremonial and traditional use: the cultural frame

Ceremonial use refers to the use of psilocybin-containing mushrooms in indigenous, religious, or spiritual contexts, often involving communal ritual, trained guides or elders, and a cosmological framework that gives the experience meaning beyond the individual. Anthropologists and historians have documented such practices among Mazatec communities in Oaxaca, Mexico, where mushrooms have been used in healing and divinatory ceremonies for generations.

In legal terms, ceremonial use occupies a distinctive space. The UN 1971 Convention on Psychotropic Substances explicitly allows signatory states to permit traditional use of certain plants — a provision negotiated partly in recognition of indigenous practices. In the United States, court rulings under the Religious Freedom Restoration Act have compelled exemptions for religious groups using psychedelic sacraments, though these remain case-by-case and narrow. The ceremonial frame differs from the therapeutic frame in that its legitimacy rests on cultural and religious grounds rather than on clinical evidence, and its governance tends to be negotiated through courts and human rights frameworks rather than medicines regulators.

Recreational use: the residual category

'Recreational' is the least defined of the three frames and frequently functions as a catch-all for any use outside clinical or ceremonial settings. In the policy literature, recreational use typically refers to self-directed use in informal contexts — at home, at social gatherings, in nature — without medical oversight, ritual structure, or a stated therapeutic intention. It is the frame most associated in public discourse with risk, though researchers note that the actual risk profile depends heavily on factors such as set, setting, and individual vulnerability, not on the label alone.

Some scholars have argued that the term 'recreational' is misleadingly dismissive, implying triviality where users may in fact be seeking personal insight, emotional processing, or spiritual experience outside formal structures. Others counter that the absence of screening, preparation, and integration genuinely does increase the likelihood of adverse outcomes, particularly for individuals with predisposing psychiatric conditions. The debate is not about whether unstructured use carries different risk considerations from structured use — most agree it does — but about whether 'recreational' adequately captures the range of motivations and contexts it is meant to describe.

Why the boundaries blur

Researchers increasingly acknowledge that the three frames share more than they differ in at their edges. The subjective effects of psilocybin — altered perception, emotional release, experiences of awe or connectedness — occur regardless of the label assigned to the setting. A participant in a clinical trial may describe their experience as mystical; a member of a ceremony may experience symptomatic relief; a person using outside any formal structure may engage in careful preparation and reflection that closely mirrors therapeutic integration.

The variable that researchers most consistently identify as important across all three frames is what the literature calls 'set and setting': the user's mindset and the physical and social environment. This is one reason that harm-reduction approaches — which accept that unstructured use occurs and focus on reducing associated risks rather than denying its existence — have gained traction in public health. The frames, in other words, are useful for policy and research design, but they are not clean boundaries in lived experience.

What this means for South African policy

In South Africa, psilocybin is classified as a Schedule 7 substance under the Medicines and Related Substances Act, meaning that the law does not distinguish between therapeutic, ceremonial, and recreational use. All are treated as criminal conduct outside of an approved clinical trial. This is the same legal logic that was challenged in the cannabis privacy rights case, where the Constitutional Court found that criminalising personal use in private was an unjustifiable infringement of the right to privacy — and it raises parallel questions for psilocybin.

Other jurisdictions have begun creating legal distinctions. Oregon's regulated services model permits supervised adult use outside a strictly medical framework. Australia's TGA rescheduling allows prescription within defined clinical parameters while leaving other forms of use illegal. The South African debate, when it matures, will likely need to decide whether to maintain a single undifferentiated legal category — or to follow the international trend toward differentiated frameworks, and how, if at all, to accommodate ceremonial use within a constitutional order that protects cultural and religious rights.